Inflammation biomarker discovery in Parkinson's disease and atypical parkinsonisms
- PMID: 31952511
- PMCID: PMC6967088
- DOI: 10.1186/s12883-020-1608-8
Inflammation biomarker discovery in Parkinson's disease and atypical parkinsonisms
Abstract
Background: Parkinson's disease (PD) and atypical parkinsonisms (APD) have overlapping symptoms challenging an early diagnosis. Diagnostic accuracy is important because PD and APD have different prognosis and response to treatment. We aimed to identify diagnostic inflammatory biomarkers of PD and APD in cerebrospinal fluid (CSF) using the multiplex proximity extension assay (PEA) technology and to study possible correlations of biomarkers with disease progression.
Methods: CSF from a longitudinal cohort study consisting of PD and APD patients (PD, n = 44; multiple system atrophy (MSA), n = 14; vascular parkinsonism (VaP), n = 9; and PD with VaP, n = 7) and controls (n = 25) were analyzed.
Results: Concentrations of CCL28 were elevated in PD compared to controls (p = 0.0001). Five other biomarkers differentiated both MSA and PD from controls (p < 0.05) and 10 biomarkers differentiated MSA from controls, of which two proteins, i.e. beta nerve growth factor (β-NGF) and Delta and Notch like epidermal growth factor-related receptor (DNER), were also present at lower levels in MSA compared to PD (both p = 0.032). Two biomarkers (MCP-1 and MMP-10) positively correlated with PD progression (rho > 0.650; p < 0.01).
Conclusions: PEA technique identified potential new CSF biomarkers to help to predict the prognosis of PD. Also, we identified new candidate biomarkers to distinguish MSA from PD.
Keywords: Biomarkers; Inflammation; Multiple system atrophy; Parkinson’s disease.
Conflict of interest statement
The authors declare that they have no competing interests.
Figures


Similar articles
-
Cerebrospinal fluid NFL in the differential diagnosis of parkinsonian disorders: A meta-analysis.Neurosci Lett. 2018 Oct 15;685:35-41. doi: 10.1016/j.neulet.2018.07.030. Epub 2018 Jul 20. Neurosci Lett. 2018. PMID: 30036569
-
Proximity extension assay testing reveals novel diagnostic biomarkers of atypical parkinsonian syndromes.J Neurol Neurosurg Psychiatry. 2019 Jul;90(7):768-773. doi: 10.1136/jnnp-2018-320151. Epub 2019 Mar 13. J Neurol Neurosurg Psychiatry. 2019. PMID: 30867224 Free PMC article.
-
CSF α-synuclein and UCH-L1 levels in Parkinson's disease and atypical parkinsonian disorders.Parkinsonism Relat Disord. 2014 Apr;20(4):382-7. doi: 10.1016/j.parkreldis.2014.01.011. Epub 2014 Jan 22. Parkinsonism Relat Disord. 2014. PMID: 24507721
-
Cerebrospinal fluid and blood neurofilament light chain in Parkinson's disease and atypical parkinsonian syndromes: a systematic review and Bayesian network meta-analysis.J Neurol. 2025 Apr 3;272(4):311. doi: 10.1007/s00415-025-13051-x. J Neurol. 2025. PMID: 40180649
-
Cerebrospinal Fluid Metabolome in Parkinson's Disease and Multiple System Atrophy.Int J Mol Sci. 2022 Feb 7;23(3):1879. doi: 10.3390/ijms23031879. Int J Mol Sci. 2022. PMID: 35163800 Free PMC article. Review.
Cited by
-
Growth Factors and Their Application in the Therapy of Hereditary Neurodegenerative Diseases.Biomedicines. 2024 Aug 20;12(8):1906. doi: 10.3390/biomedicines12081906. Biomedicines. 2024. PMID: 39200370 Free PMC article. Review.
-
Neurodegeneration and inflammation crosstalk: Therapeutic targets and perspectives.IBRO Neurosci Rep. 2022 Dec 16;14:95-110. doi: 10.1016/j.ibneur.2022.12.003. eCollection 2023 Jun. IBRO Neurosci Rep. 2022. PMID: 37388502 Free PMC article.
-
Quantitative and causal analysis for inflammatory genes and the risk of Parkinson's disease.Front Immunol. 2023 Feb 28;14:1119315. doi: 10.3389/fimmu.2023.1119315. eCollection 2023. Front Immunol. 2023. PMID: 36926335 Free PMC article.
-
Proximity Elongation Assay and ELISA for the Identification of Serum Diagnostic Biomarkers in Parkinson's Disease and Progressive Supranuclear Palsy.Int J Mol Sci. 2024 Oct 30;25(21):11663. doi: 10.3390/ijms252111663. Int J Mol Sci. 2024. PMID: 39519214 Free PMC article.
-
Neuroimaging and fluid biomarkers in Parkinson's disease in an era of targeted interventions.Nat Commun. 2024 Jul 5;15(1):5661. doi: 10.1038/s41467-024-49949-9. Nat Commun. 2024. PMID: 38969680 Free PMC article. Review.
References
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous